Autologous mesenchymal stem cells have a positive effect on progressive multiple sclerosis

Takeaway

  • Individuals with progressive multiple sclerosis (MS) who were treated with autologous mesenchymal stem cells (MSC), either intravenously or intrathecally, had improvements in their Expanded Disability Status Scale (EDSS) scores and had fewer relapses.

Why this matters

    The study should be used as a foundation for future clinical trials and provides clinical evidence for the safety of administering MSC in people with progressive MS who previously had an unmet treatment need.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.